Show simple item record

dc.contributor.authorLatourelle, Jeanne Cen_US
dc.contributor.authorDybdahl, Mereteen_US
dc.contributor.authorDestefano, Anita Len_US
dc.contributor.authorMyers, Richard Hen_US
dc.contributor.authorLash, Timothy Len_US
dc.date.accessioned2011-12-29T22:21:53Z
dc.date.available2011-12-29T22:21:53Z
dc.date.copyright2010en_US
dc.date.issued2010-4-12en_US
dc.identifier.citationLatourelle, Jeanne C, Merete Dybdahl, Anita L Destefano, Richard H Myers, Timothy L Lash. "Risk of Parkinson's disease after tamoxifen treatment" BMC Neurology 10:23. (2010)en_US
dc.identifier.issn1471-2377en_US
dc.identifier.urihttp://hdl.handle.net/2144/2570
dc.description.abstractBACKGROUND: Women have a reduced risk of developing Parkinson's disease (PD) compared with age-matched men. Neuro-protective effects of estrogen potentially explain this difference. Tamoxifen, commonly used in breast cancer treatment, may interfere with the protective effects of estrogen and increase risk of PD. We compared the rate of PD in Danish breast cancer patients treated with tamoxifen to the rate among those not treated with tamoxifen. METHODS: A cohort of 15,419 breast cancer patients identified from the Danish Breast Cancer Collaborative Group database was linked to the National Registry of Patients to identify PD diagnoses. Overall risk and rate of PD following identification into the study was compared between patients treated with tamoxifen as adjuvant hormonal therapy and patients not receiving tamoxifen. Time-dependent effects of tamoxifen treatment on PD rate were examined to estimate the likely induction period for tamoxifen. RESULTS: In total, 35 cases of PD were identified among the 15,419 breast cancer patients. No overall effect of tamoxifen on rate of PD was observed (HR = 1.3, 95% CI: 0.64-2.5), but a PD hazard ratio of 5.1 (95% CI: 1.0-25) was seen four to six years following initiation of tamoxifen treatment. CONCLUSIONS: These results provide evidence that the neuro-protective properties of estrogen against PD occurrence may be disrupted by tamoxifen therapy. Tamoxifen treatments may be associated with an increased rate of PD; however these effects act after four years, are of limited duration, and the adverse effect is overwhelmed by the protection against breast recurrence conferred by tamoxifen therapy.en_US
dc.description.sponsorshipPublic Health Service(R01 NS36711-09); Aahus University Hospital Department of Clinincal Epidemiology's Research Foundationen_US
dc.language.isoenen_US
dc.publisherBioMed Centralen_US
dc.rightsCopyright 2010 Latourelle et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en_US
dc.rights.urihttp://creativecommons.org/licenses/by/2.0en_US
dc.titleRisk of Parkinson's Disease after Tamoxifen Treatmenten_US
dc.typearticleen_US
dc.identifier.doi10.1186/1471-2377-10-23en_US
dc.identifier.pubmedid20385012en_US
dc.identifier.pmcid2862029en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Copyright 2010 Latourelle et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Except where otherwise noted, this item's license is described as Copyright 2010 Latourelle et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.